CYTK
Cytokinetics Incorporated (Nasdaq: CYTK) announced the first commercial European launch of MYQORZO...
Article Summary
BUY- Cytokinetics Incorporated (Nasdaq: CYTK) announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (oHCM) in adult patients, following European Commission approval in February 2026 based on positive results from SEQUOIA-HCM pivotal Phase 3 clinical trial demonstrating robust efficacy, safety, and clinically meaningful benefits across symptoms, exercise capacity, hemodynamics, and biomarker endpoints published in New England Journal of Medicine.
- The allosteric and reversible inhibitor of cardiac myosin motor activity reduces cardiac contractility and LVOT obstruction in patients with oHCM, with treatment with aficam ten for 24 weeks significantly improving exercise capacity compared to placebo, increasing peak oxygen uptake by 1.76 mL/kg/min measured by cardiopulmonary exercise testing (CPET) compared to baseline in patients treated with MYQorzO versus 0.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 450.6% | 25% | 100.0 ptsExceptional (450.6%) - Hypergrowth |
| EPS Growth Next 5Y ? | 35.4% | 25% | 90.0 ptsExcellent (35.4%) - Strong outlook |
| Target Price Upside ? | 39.9% | 20% | 85.0 ptsLarge Upside (39.9%) - Target: $104.70 vs Current: $74.85 |
| Gross Margin % ? | 87.0% | 15% | 100.0 ptsExceptional (87.0%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -6.7% | 15% | 20.0 ptsBarely a Dip (-6.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About CYTK
- Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
- The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
- It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
- In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.
- Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.